Stuttgart - Delayed Quote EUR

Amgen Inc (AMG.SG)

242.50

-0.65

(-0.27%)

At close: 9:12:20 PM GMT+2

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. Three Fool.com contributors believe they've identified relatively safe growth stocks in the healthcare sector that you can buy and hold. Here's why they picked Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Motley Fool 8 hours ago

VRTX

LLY

AMGN
Is Amgen Inc. (AMGN) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview […]

Insider Monkey 8 hours ago

AMGN
Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.

Investing.com 8 hours ago

ABBV

LLY

GILD
Amgen (AMGN) Stock Moves -1.3%: What You Should Know

Amgen (AMGN) concluded the recent trading session at $273.68, signifying a -1.3% move from its prior day's close.

Zacks yesterday

AMGN
Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks yesterday

AMGN
Here's Why Amgen (AMGN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 4 days ago

AMGN
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

In the closing of the recent trading day, Amgen (AMGN) stood at $277.29, denoting a -1.89% change from the preceding trading day.

Zacks 4 days ago

AMGN
Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private […]

Insider Monkey 5 days ago

AMGN
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans. Let's consider two such corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).

Motley Fool 5 days ago

AMGN

NVS
Sector Update: Health Care Stocks Rise Monday Afternoon

Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the

PREMIUM
MT Newswires 8 days ago

IRWD

AMGN

PFE
Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

Pharmaceutical Technology 8 days ago

AMGN

GLDAF
Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC

The randomised, controlled study aims to assess the therapy’s safety and efficacy.

Clinical Trials Arena 8 days ago

AMGN
Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of its blockbuster medicine, Enbrel (etanercept). Sandoz alleges Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi, by unlawfully purchasing and using certain patent rights to entrench its dominant market position. Amgen said it did not comment on pending litigation.

Reuters 8 days ago

AMGN
Amgen (AMGN) Gains But Lags Market: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $285.92, marking a +1.6% move from the previous day.

Zacks 10 days ago

AMGN
Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Health care stocks advanced late Friday afternoon with the NYSE Health Care Index adding 1.8% and th

PREMIUM
MT Newswires 11 days ago

AMGN
Sector Update: Health Care Stocks Gain in Afternoon Trading

Health care stocks advanced Friday afternoon, with the NYSE Health Care Index adding 1.9% and the He

PREMIUM
MT Newswires 11 days ago

AMGN
Amgen (NasdaqGS:AMGN) Clinical Trial Success In SCLC Treatment With IMDELLTRA

Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for its DeLLphi-304 trial assessing IMDELLTRA for small cell lung cancer. These product advancements likely buoyed the company's recent quarterly price increase of 7.31%. Moreover, broader market movements contributed to shifts in Amgen's stock. Notably, the volatile trading activity, which saw the Dow and other indexes rally, subdued inflation data, and mixed economic...

Simply Wall St. 11 days ago

AMGN
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy.

PR Newswire 11 days ago

AMGN
Pharma’s US manufacturing moment: Where companies are making the biggest moves

The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.

Pharma Voice 11 days ago

AMGN

LLY

NVO
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

Zacks 12 days ago

PCRX

SRPT

EWTX

Performance Overview

Return	AMG.SG	S&P 500 (^GSPC)
YTD	-3.18%	-10.10%
1-Year	-1.49%	+5.53%
3-Year	+14.63%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc (AMG.SG)

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

Is Amgen Inc. (AMGN) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Amgen (AMGN) Stock Moves -1.3%: What You Should Know

Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?

Here's Why Amgen (AMGN) is a Strong Value Stock

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Sector Update: Health Care Stocks Rise Monday Afternoon

Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit

Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC

Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug

Amgen (AMGN) Gains But Lags Market: What You Should Know

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Sector Update: Health Care Stocks Gain in Afternoon Trading

Amgen (NasdaqGS:AMGN) Clinical Trial Success In SCLC Treatment With IMDELLTRA

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Pharma’s US manufacturing moment: Where companies are making the biggest moves

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Performance Overview